Showing 5091-5100 of 5621 results for "".
- Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in US IDE Trial for iStent infinitehttps://modernod.com/news/glaukos-achieves-pipeline-milestone-with-completion-of-patient-enrollment-in-us-ide-trial-for-istent-infinite/2476990/Glaukos announced the completion of patient enrollment in its FDA Investigational Device Exemption (IDE) trial for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is designed for use in a standalone procedure to reduce elevated IOP in refractory glaucoma patients. I
- Aerpio Pharmaceuticals Announces Interim Results from its Phase 1b Clinical Trial of AKB-9778 for Primary Open Angle Glaucomahttps://modernod.com/news/aerpio-pharmaceuticals-announces-interim-results-from-its-phase-1b-clinical-trial-of-akb-9778-for-primary-open-angle-glaucoma/2476991/Aerpio Pharmaceuticals announced interim results from its phase 1b clinical trial of a topical ocular formulation of AKB-9778 in development as a potential treatment for primary open angle glaucoma (POAG). The phase 1b study is an ongoing randomized, double-masked study designed to assess
- Harbour BioMed Announces Completion of Phase 2 Study in China of HBM9036 In Patients With Moderate-to-Severe Dry Eye Diseasehttps://modernod.com/news/harbour-biomed-announces-completion-of-phase-2-study-in-china-of-hbm9036-in-patients-with-moderate-to-severe-dry-eye-disease/2476993/Harbour BioMed (HBM) announced completion of a phase 2 study in China of HBM9036 (tanfanercept), a new, investigational TNF receptor-1 fragment, in adult patients with moderate-to-severe dry eye disease (DED). The study results, combined with previous results from HBM’s partner HanAll’s clinical
- On World Sight Day, Allergan Launches National Campaign to Raise Awareness of Glaucomahttps://modernod.com/news/on-world-sight-day-allergan-launches-national-campaign-to-raise-awareness-of-glaucoma/2476984/Allergan announced a national education campaign called “My Glaucoma.” The campaign is designed to help people understand the burden of living with glaucoma and empower those with the disease and their caregivers to feel comfortable speaking with their doctor about a treatment
- Neurolign Acquires of Eye Diagnostic Technology Company Neuro Kineticshttps://modernod.com/news/neurolign-acquires-of-eye-diagnostic-technology-company-neuro-kinetics/2476981/Neurolign Technologies announced the acquisition of Neuro Kinetics of Pittsburgh, Pennsylvania, a provider of clinical eye-tracking and noninvasive neurofunctional diagnostic testing, delivering neurofunctional assessments. Terms of the deal were not disc
- Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopiahttps://modernod.com/news/orasis-pharmaceuticals-announces-csf-1-eye-drop-successfully-met-primary-endpoint-in-phase-2b-clinical-study-in-presbyopia/2476977/Orasis Pharmaceuticals announced its CSF-1 eye drop has successfully met the primary endpoint in a phase 2b clinical study in individuals with presbyopia. CSF-1 successfully demonstrated statistically sig
- Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstenthttps://modernod.com/news/ivantis-completes-enrollment-of-international-spectrum-registry-for-hydrus-microstent/2476973/Ivantis announced that it has completed enrollment in its SPECTRUM, which the company calls the largest single-device registry in ophthalmology. SPECTRUM is a patient registry for the Hydrus Microstent, a microinvasive glaucoma surgery (MIGS) device to treat patients with mild to moderate
- LLamasoft Partners with Global Eye Bank, Eversighthttps://modernod.com/news/llamasoft-partners-with-global-eye-bank-eversight/2476974/LLamasoft has announced its partnership with Eversight, a nonprofit organization dedicated to restoring sight and preventing blindness through eye donation, corneal transplantation, and vision research. Eversight will utilize LLamasoft’s solutions to make data-driven decisions that more accuratel
- Ocutrx Unveils ORLenz for Surgery Visualization Technology in ARWear Headsethttps://modernod.com/news/ocutrx-unveils-orlenz-for-surgery-visualization-technology-in-arwear-headset/2476972/Ocutrx Vision Technologies is revealing a next-generation AR headset technology for surgery visualization called the ORLenz. A prototype of this technology is being formally introduced at the American Academy of Ophthalmology 2019 Conference in San Francisco. The ORLenz is a second medical device
- Canon USA to Showcase Eyecare Solutions At AAOhttps://modernod.com/news/canon-usa-to-showcase-eyecare-solutions-at-aao/2476971/Canon U.S.A. will be showcasing the recently FDA 510(k) cleared Xephilio OCT-A1 Optical Coherence Tomography device, together with the required RX Capture software, computer and LCD monitor,collectively, the “Xephilio OCT-A1 System, at the American Academy o